DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
28.13B
Market cap28.13B
Price-Earnings ratio
34.98
Price-Earnings ratio34.98
Dividend yield
Dividend yield
Average volume
5.79M
Average volume5.79M
High today
$73.61
High today$73.61
Low today
$70.81
Low today$70.81
Open price
$73.08
Open price$73.08
Volume
4.14M
Volume4.14M
52 Week high
$91.87
52 Week high$91.87
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $73.09. The company's market cap stands at 28.13B, with a P/E ratio of 34.98.

As of 2026-02-25, DexCom(DXCM) stock has fluctuated between $70.81 and $73.61. The current price stands at $73.09, placing the stock +3.2% above today's low and -0.7% off the high.

The DexCom(DXCM)'s current trading volume is 4.14M, compared to an average daily volume of 5.79M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $91.87 and a 52-week low of $54.11.

In the last year, DexCom(DXCM) shares hit a 52-week high of $91.87 and a 52-week low of $54.11.

DXCM News

Simply Wall St 16h
How DexCom’s Strong 2025 Results, Guidance and Buyback Have Changed Its Investment Story

In February 2026, DexCom reported past fourth-quarter 2025 results showing sales of US$1,259.6 million and net income of US$267.3 million, alongside full-year 2...

How DexCom’s Strong 2025 Results, Guidance and Buyback Have Changed Its Investment Story
Simply Wall St 2d
DexCom G7 Rollout And Expansion Shape Growth And Competitive Outlook

DexCom highlighted strong momentum from the successful U.S. rollout of its G7 15 day sensor system in its latest results. Management pointed to encouraging ear...

DexCom G7 Rollout And Expansion Shape Growth And Competitive Outlook
Simply Wall St 6d
The Strong Earnings Posted By DexCom Are A Good Indication Of The Strength Of The Business

Even though DexCom, Inc.'s ( ) recent earnings release was robust, the market didn't seem to notice. Our analysis suggests that investors might be missing some...

The Strong Earnings Posted By DexCom Are A Good Indication Of The Strength Of The Business

Analyst ratings

82%

of 33 ratings
Buy
81.8%
Hold
15.2%
Sell
3%

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.